Gapping down
In reaction to earnings/guidance:
- SI -13.9%, GS -3.6%, HAIN -2%, XERS -1.8%, BK -1%
Select travel related names showing early weakness:
- DAL -1.9%, CCL -1.7%, RCL -1.5%, AAL -1.3%, UAL -1.2%, LUV -1.2%, JBLU -0.9%, SAVE -0.9%
Other news:
- MOLN -14.5% (Molecular Partners and Novartis (NVS) finalize license agreement for Ensovibep for COVID-19)
- EVLO -3.9% (Presents Data on EDP1815)
- CS -3.5% (appoints Axel P. Lehmann as new Chairman; António Horta-Osório has resigned)
- LGO -3.1% (FY21 production)
- AGI -2.7% (FY21 production)
- BLUE -1.7% (provides FDA update on review timelines for Betibeglogene Autotemcel)
- RIO -1.5% (reports FY21 Pilbara iron ore production declined 4% yr/yr)
- NCLH -1.2% (opts into CDC's COVID-19 Program for Cruise Ships Operating in U.S. Waters)
Analyst comments:
- ABNB -3.6% (downgraded to Hold from Buy at Gordon Haskett)
- SRAD -2.9% (downgraded to Equal-Weight from Overweight at Morgan Stanley )
- ATUS -2.2% (downgraded to Underperform from Neutral at Exane BNP Paribas)
- SHW -1.8% (downgraded to Equal Weight from Overweight at Wells Fargo)
- BDN -1.4% (downgraded to Hold from Buy at Truist)
- CHTR -1.3% (downgraded to Neutral from Outperform at Exane BNP Paribas)
- CHH -1.1% (downgraded to Underweight from Equal-Weight at Morgan Stanley)